TRAW Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
-100.0%
2.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
-100.0%
2.7M
Operating Expenses
3.2M
-54.3%
6.9M
-5.7%
7.4M
+81.7%
4.1M
+1.8%
4.0M
R&D
1.1M
-77.6%
4.9M
-2.4%
5.0M
+117.9%
2.3M
+0.9%
2.3M
SG&A
3.5M
+71.0%
2.0M
-12.8%
2.3M
+33.8%
1.7M
+3.1%
1.7M
Operating Income
-3175000
+54.3%
-6946000
+5.7%
-7368000
-81.7%
-4055000
-224.7%
-1249000
EBITDA
-3131000
+54.6%
-6902000
+5.8%
-7324000
-81.3%
-4040000
-223.7%
-1248000
Net Income
-3054000
+57.0%
-7107000
+4.5%
-7443000
-87.9%
-3962000
-333.0%
-915000
EPS (Basic)
$-0.16
+69.8%
$-0.53
-10.4%
$-0.48
-41.2%
$-0.34
-209.1%
$-0.11
EPS (Diluted)
$-0.16
+69.8%
$-0.53
-15.2%
$-0.46
-35.3%
$-0.34
-209.1%
$-0.11
Shares (Diluted)
15.9M
+49.1%
10.6M
-8.7%
11.7M
+32.1%
8.8M
+51.5%
5.8M
Traws Pharma (TRAW) โ€” Financials